These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26183118)

  • 21. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
    Corrao G; Conti V; Merlino L; Catapano AL; Mancia G
    Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Few sex differences in the use of drugs for secondary prevention after stroke: a nationwide observational study.
    Sjölander M; Eriksson M; Glader EL
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):911-9. PubMed ID: 22069216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review.
    Bitton A; Choudhry NK; Matlin OS; Swanton K; Shrank WH
    Am J Med; 2013 Apr; 126(4):357.e7-357.e27. PubMed ID: 23507208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does age modify effectiveness of statin therapy in coronary artery disease?
    Pletcher MJ; Coxson PG
    Ann Intern Med; 2010 Jun; 152(12):825; author reply 825-6. PubMed ID: 20547915
    [No Abstract]   [Full Text] [Related]  

  • 25. [Secondary prevention of patients with ischaemic heart disease--the reduction of LDL cholesterol level and the regression of atherosclerosis].
    Bárczi G; Merkely B
    Lege Artis Med; 2007 Oct; 17(10):675-9. PubMed ID: 19227597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ischemia and No Obstructive Coronary Artery Disease ( INOCA ): What Is the Risk?
    Herscovici R; Sedlak T; Wei J; Pepine CJ; Handberg E; Bairey Merz CN
    J Am Heart Assoc; 2018 Sep; 7(17):e008868. PubMed ID: 30371178
    [No Abstract]   [Full Text] [Related]  

  • 27. The COACH program produces sustained improvements in cardiovascular risk factors and adherence to recommended medications-two years follow-up.
    Jelinek M; Vale MJ; Liew D; Grigg L; Dart A; Hare DL; Best JD
    Heart Lung Circ; 2009 Dec; 18(6):388-92. PubMed ID: 19648058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging clinical challenges in the use of statins.
    Hennekens CH; Breuer NR; Gelb IJ; Bjorkman DJ; Borer JS; Pfeffer MA
    Am J Med; 2013 Aug; 126(8):663-4. PubMed ID: 23786669
    [No Abstract]   [Full Text] [Related]  

  • 29. Percutaneous coronary intervention vs. optimal medical therapy--the other side of the coin: medication adherence.
    Kocas C; Abaci O; Oktay V; Coskun U; Bostan C; Yildiz A; Arat Ozkan A; Gurmen T; Ersanli M
    J Clin Pharm Ther; 2013 Dec; 38(6):476-9. PubMed ID: 23992279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial.
    McAlister FA; Majumdar SR; Lin M; Bakal J; Fradette M; Anderson T
    Can J Cardiol; 2014 Dec; 30(12):1627-32. PubMed ID: 25307535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of Premature Coronary Artery Calcification in Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease.
    Khetarpal SA; Honigberg MC; Natarajan P
    JAMA Cardiol; 2021 Nov; 6(11):1233-1234. PubMed ID: 34495295
    [No Abstract]   [Full Text] [Related]  

  • 32. Ask the doctors. I am 71 years old, have chronic kidney failure, and am on dialysis. I know my overall outlook is not good, and I wonder whether it is worth it to take a statin to control my cholesterol.
    Lee T; Lee R
    Harv Heart Lett; 2012 Dec; 23(4):2. PubMed ID: 23476941
    [No Abstract]   [Full Text] [Related]  

  • 33. Secondary prevention of ischemic heart disease: closing the gap.
    Fainaru M
    Isr Med Assoc J; 2005 Jun; 7(6):400-1. PubMed ID: 15984387
    [No Abstract]   [Full Text] [Related]  

  • 34. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes.
    Choudhry NK; Glynn RJ; Avorn J; Lee JL; Brennan TA; Reisman L; Toscano M; Levin R; Matlin OS; Antman EM; Shrank WH
    Am Heart J; 2014 Jan; 167(1):51-58.e5. PubMed ID: 24332142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving Medication Adherence in Cardiovascular Disease Prevention: What's New?
    Ogungbe O; Dennison Himmelfarb CR; Commodore-Mensah Y
    J Cardiovasc Nurs; 2020; 35(1):6-10. PubMed ID: 31804246
    [No Abstract]   [Full Text] [Related]  

  • 36. Type 2 diabetes in well-controlled hypertension.
    Yatsuya H; Yamagishi K; Jacobs DR
    Circ J; 2011; 75(10):2316-7. PubMed ID: 21873800
    [No Abstract]   [Full Text] [Related]  

  • 37. Appropriateness of statins in patients aged ≥80 years and comparison to other age groups.
    Chokshi NP; Messerli FH; Sutin D; Supariwala AA; Shah NR
    Am J Cardiol; 2012 Nov; 110(10):1477-81. PubMed ID: 22901970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary prevention of myocardial infarction: putting the evidence to use.
    Herzog E; Javed F
    Arch Intern Med; 2010 Aug; 170(15):1381-2. PubMed ID: 20696965
    [No Abstract]   [Full Text] [Related]  

  • 39. Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?
    Singh M; Chin SH; Giles PD; Crothers D; Al-Allaf K; Khan JM
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):556-61. PubMed ID: 20305563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selection of the Best of 2017 in Ischemic Heart Disease.
    Martín-Asenjo R; Aboal J; Masip J; López de Sá E; Sionis A
    Rev Esp Cardiol (Engl Ed); 2018 Feb; 71(2):124-125. PubMed ID: 29221699
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.